ELIQUIS is available for the prevention of stroke / systemic embolism in patients with NVAF
EXPLORE DATA IN NVAFELIQUIS is available for the treatment and prevention of recurrent DVT / PE
EXPLORE DATA IN DVT / PENow is the time to offer your patients ELIQUIS – it's simple to initiate or switch
GO TO DOSING AND SWITCHINGPlease click here to access the ELIQUIS Patient Information Leaflet.
BD = Twice Daily
DVT = Deep Vein Thrombosis
NVAF = Non-Valvular Atrial Fibrillation
PE = Pulmonary Embolism
SmPC = Summary of Product Characteristics
* ELIQUIS® (apixaban): an oral, direct factor Xa inhibitor indicated for:
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA);
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
- Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery1
†Not all patients who start on ELIQUIS for acute DVT / PE will stay on ELIQUIS; some acute DVT / PE patients who receive treatment do not require treatment for the prevention of recurrent DVT / PE. Other patients may be prescribed ELIQUIS for the prevention of recurrent VTE after initial treatment for acute DVT / PE with another anticoagulant.1 This is a decision for the prescribing clinician together with patient involvement in the decision-making.
Reference
- ELIQUIS® (apixaban) Summary of Product Characteristics.